On a quick point of order, Madam Chair, given the fact that the revamping of the Food and Drugs Act is so intertwined with what we're studying in terms of post-market surveillance, what assurances can you give us that what we're doing has any meaning if in fact the government is on a deadline and a schedule of a 30-day consultation period and is bringing forward legislation? How can we have a meaningful role in that when in fact our schedule goes much beyond 30 days?
On January 31st, 2008. See this statement in context.